- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00195793
A 16 Week Comparative Study of Fenofibrate Versus Ezetimibe as Add-on Therapy to Atorvastatin
October 2, 2007 updated by: Abbott
A Multicenter, Randomized, Double-Blind, Prospective, Parallel Study to Compare the Safety and Efficacy of Fenofibrate or Ezetimibe as Add-On Therapy to Atorvastatin in Subjects With Combined Hyperlipidemia, Typical of the Metabolic Syndrome
The objective of this study is to evaluate the effects of adding Tricor 145 mg to once daily atorvastatin 20 mg on CHD lipid laboratory parameters.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
174
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject is >= 18 years of age, any race, and any gender.
Subjects must have the following fasting parameters:
- LDL-C > 100 mg/dL and < 190 mg/dL.
- TG level >= 175 mg/dL and < 1000 mg/dL.
- HDL-C < 40 mg/dL (men) and < 50 mg/dL (women).
Subjects must have one or more of the following:
- Treated or untreated hypertension defined as blood pressure (BP)
- 130 mmHg >= 85 mmHg (systolic / diastolic).
- Waist circumference > 88 cm (35 inches) for women or > 102 cm (40 inches) for men.
- Fasting glucose defined as >= 100 mg/dL but <= 125 mg/dL.
- Subject has, in the opinion of the investigator, a life expectancy greater than 6 months.
- Female subjects must have a negative pregnancy test prior to study enrollment.
- Female subjects of child bearing potential must agree to practice an effective barrier method of birth control for the duration of the study.
- Subject must be willing to observe the Step I Diet recommended by the NCEP throughout the study.
- Subject must be willing to participate in the study and to complete all follow-up assessments.
Exclusion Criteria:
- Subject has a known hypersensitivity to fenofibrate, ezetimibe, or atorvastatin
- Subject has been previously enrolled in this study.
- Subject has used an investigational drug within 30 days of study entry.
- Subject has been diagnosed with Type I or Type II Diabetes Mellitus or is currently being treated with anti-diabetic medication, or has a fasting glucose >= 126 mg/dL.
- Subject has a history of pancreatitis or cholelithiasis or a history of gastric or duodenal ulcer within 3 months of study entry.
- Subject has hematologic, digestive, or central nervous system disorder including cerebrovascular disease or degenerative disease that would limit study evaluation or participation.
- Subject has had a myocardial infarction, coronary bypass surgery, or angioplasty within 6 months of study entry.
- Subject has unstable or severe peripheral artery disease within 3 months of study entry.
- Subject has unstable angina pectoris or uncontrolled cardiac arrhythmias.
- Subject has congestive heart failure (CHF) as defined by NYHA Class III or IV
- Subject has coagulopathy (PT or PTT > 1.25 times control).
- Subject has known impairment of renal function (serum creatinine > 1.5 mg/dL), dysproteinemia, nephrotic-range proteinuria, or other renal disease.
- Subject has active or chronic hepatobiliary or hepatic disease (subjects with AST or ALT > 2 times the upper limit of the central laboratory reference range).
- Subject is pregnant or lactating.
- Subject is receiving hormonal therapy.
- Subject has a known history of thyroid disease or other endocrine abnormality.
- Subject has a history of diagnosed hereditary or acquired myopathy.
- Subject is known to be HIV positive.
- Subject has a history of mental instability, drug or alcohol (as defined by greater than 14 drinks per week) abuse, or subject has been treated for severe psychiatric illness, which, in the opinion of the investigator, may interfere with optimal participation in the study.
- Subject has received a solid organ transplant.
- Subject has a clinically significant, unstable, uncontrolled disease that could be adversely affected by study participation.
- Subject is unwilling or unable to consent to enter the study.
- Subject is, in the opinion of the investigator, unable to comply with the requirements of the study protocol or is unsuitable for the study for any reason.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percent change from Combination Baseline to 12 weeks post-Combination Baseline in direct measured HDL-C and TG.
Time Frame: Week 12
|
Week 12
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Advanced lipid and inflammatory parameters
Time Frame: Week 12
|
Week 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Global Medical Information, Abbott
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2004
Study Registration Dates
First Submitted
September 14, 2005
First Submitted That Met QC Criteria
September 14, 2005
First Posted (Estimate)
September 20, 2005
Study Record Updates
Last Update Posted (Estimate)
October 4, 2007
Last Update Submitted That Met QC Criteria
October 2, 2007
Last Verified
October 1, 2007
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Metabolic Diseases
- Lipid Metabolism Disorders
- Dyslipidemias
- Hyperlipidemias
- Hyperlipoproteinemias
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Atorvastatin
- Fenofibrate
- Ezetimibe
Other Study ID Numbers
- M03-661
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperlipidemia
-
Drug Commission of the German Medical AssociationMadaus AGTerminatedHypercholesterolemia | Combined Hyperlipidemia
-
Misr University for Science and TechnologyActive, not recruiting
-
DongKoo Bio & PharmaUnknownHyperlipidemia, HypertriglyceridemiaKorea, Republic of
-
Jiangsu HengRui Medicine Co., Ltd.CompletedHypercholesterolemia and HyperlipidemiaChina
-
Jeil Pharmaceutical Co., Ltd.CompletedHypertension With HyperlipidemiaKorea, Republic of
-
PfizerWithdrawnPrimary Hyperlipidemia or Mixed DyslipidemiaChina
-
ShionogiIntegriumCompletedCombined HyperlipidemiaUnited States
-
IlDong Pharmaceutical Co LtdCompletedHypertension With HyperlipidemiaKorea, Republic of
-
HK inno.N CorporationCompletedHypertension With Hyperlipidemia
-
LG Life SciencesCompletedHypertension, HyperlipidemiaKorea, Republic of
Clinical Trials on atorvastatin
-
GlaxoSmithKlineCompletedDiabetes Mellitus, Type 2Korea, Republic of, Malaysia, Philippines, Thailand, Russian Federation, Mexico
-
Organon and CoCompleted
-
Obafemi Awolowo University Teaching HospitalOpen PhilanthropyRecruitingTuberculosis | Pulmonary Tuberculosis | Koch's DiseaseNigeria
-
Hippocration General HospitalCompletedCoronary Artery Disease | Atherosclerosis | Endothelial Dysfunction | Oxidative Stress | HMG-CoA Reductase Inhibitor ToxicityGreece
-
PfizerCompletedHypertriglyceridemia | Hyperlipoproteinemia Type IVUnited States, Canada
-
Organon and CoCompleted
-
Zhejiang Hisun Pharmaceutical Co. Ltd.Unknown
-
St. Olavs HospitalUllevaal University Hospital; Oslo University Hospital; University Hospital of... and other collaboratorsNot yet recruiting
-
Zhongda HospitalNot yet recruitingAcute Ischemic Stroke | Mechanical ThrombectomyChina